These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 24931673)

  • 1. Determination of personalized diabetes treatment plans using a two-delay model.
    Kissler SM; Cichowitz C; Sankaranarayanan S; Bortz DM
    J Theor Biol; 2014 Oct; 359():101-11. PubMed ID: 24931673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical investigation of diabetically impaired ultradian oscillations in the glucose-insulin regulation.
    Huard B; Bridgewater A; Angelova M
    J Theor Biol; 2017 Apr; 418():66-76. PubMed ID: 28130099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
    Ehlers MR; Klaff LJ; D'Alessio DA; Brazg R; Kay HD; Harley RE; Mathisen AL; Schneider R
    Horm Metab Res; 2003 Oct; 35(10):611-6. PubMed ID: 14605997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
    Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
    Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
    Mu PW; Chen YM; Lu HY; Wen XQ; Zhang YH; Xie RY; Shu J; Wang MM; Zeng LY
    Diabetes Metab Res Rev; 2012 Mar; 28(3):236-40. PubMed ID: 21898754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiabetic agents.
    Francisco GE
    Prim Care; 1990 Sep; 17(3):499-519. PubMed ID: 2236334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bedtime administration of metformin may reduce insulin requirements].
    Ravina A; Minuchin O
    Harefuah; 1990 Oct; 119(7-8):200-3. PubMed ID: 2258095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the efficacy of metformin-glibenclamide treatment in overweight non-insulin dependent diabetics].
    Laurenti O; Bravi MC; Faldetta MC; De Mattia G
    Clin Ter; 1992 Mar; 140(3):259-63. PubMed ID: 1568370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Oral antidiabetic agents: recent aspects].
    Keller U; Berger W
    Schweiz Med Wochenschr; 1983 Apr; 113(17):645-50. PubMed ID: 6191388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin therapy and exercise.
    Kourtoglou GI
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S73-7. PubMed ID: 21864755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery.
    Klonoff DC
    Pediatr Endocrinol Rev; 2003 Dec; 1(2):94-100. PubMed ID: 16437014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effectiveness of combined insulin and sulfonylurea in treating non-insulin dependent diabetic patients].
    Sun Y; Xiong Y; Yang J
    Zhonghua Nei Ke Za Zhi; 1995 Apr; 34(4):246-9. PubMed ID: 7587604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized mechanistic models for exercise, meal and insulin interventions in children and adolescents with type 1 diabetes.
    Balakrishnan NP; Samavedham L; Rangaiah GP
    J Theor Biol; 2014 Sep; 357():62-73. PubMed ID: 24828465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.
    Kabadi MU; Kabadi UM
    Ann Pharmacother; 2003 Nov; 37(11):1572-6. PubMed ID: 14565810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations sulfonylurea and insulin therapy in diabetes mellitus.
    Kabadi UM; Kabadi MM
    Compr Ther; 1995 Dec; 21(12):731-6. PubMed ID: 8789138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic management of the secondary failure of sulfonylurea therapy].
    Sauer H
    Dtsch Med Wochenschr; 1985 Jan; 110(1):27-30. PubMed ID: 3880697
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.